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The inﬂammatory process has direct eﬀects on normal and abnormal wound healing. Hypertrophic scar formation is an aberrant
form of wound healing and is an indication of an exaggerated function of ﬁbroblasts and excess accumulation of extracellular
matrix during wound healing. Two cytokines—transforming growth factor-β (TGF-β) and prostaglandin E2 (PGE2)—are lipid
mediators of inﬂammation involving wound healing. Overproduction of TGF-β and suppression of PGE2 are found in excessive
wound scarring compared with normal wound healing. Nonsteroidal anti-inﬂammatory drugs (NSAIDs) or their selective
cyclooxygenase-2 (COX-2) inhibitors are frequently used as a pain-killer. However, both NSAIDs and COX-2 inhibitors inhibit
PGE2 production, which might exacerbate excessive scar formation, especially when used during the later proliferative phase.
Therefore, a balance between cytokines and medication in the pathogenesis of wound healing is needed. This report is a literature
review pertaining to wound healing and is focused on TGF-β and PGE2.
1.Introduction
Prostaglandin (PG) E2 (PGE2), synthesized from arachi-
donic acid by cyclooxygenases (COX) and synthases (PGES),
acts as both an inﬂammatory mediator and ﬁbroblast
modulator [1]. The release of PGE2 from skin tissue
after toxic stimuli produces local edema and hyperalge-
sia [2]. PGE2 is the lipid mediator of inﬂammation in
diseases, such as rheumatoid arthritis and osteoarthritis,
and is also involved in skin inﬂammation. Conventionally,
nonsteroidal anti-inﬂammatory drugs (NSAIDs) or their
selective cyclooxygenase-2 (COX-2) inhibitors are reported
to inhibit PGE2 production and act as eﬀective pain-killers,
since they are able to reduce inﬂammation successfully [3,
4]. In addition, NSAIDs are relatively inexpensive, readily
available and familiar; they are often prescribed and used
postoperatively for pain control [5]. However, the impact of
NSAIDs or COX-2 inhibitors on wound healing is highly
controversial, since in theory, an anti-inﬂammatory agent,
like one of the COX-2 inhibitors, may have a negative eﬀect
on wound healing.2 Mediators of Inﬂammation
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Figure 1: Wound healing of fetal skin with little scarring. Very little inﬂammatory reaction occurs in fetal skin, which results in little scarring
and nearly perfect recovery of fetal skin. Several environment and intrinsic factors are believed to play a role in this process.
The inﬂammatory process has direct eﬀects on normal
and abnormal wound healing. Clinical experience suggests
that hypertrophic scar formation is an aberrant form of
wound healing [6], involving an exaggerated function of
ﬁbroblasts and excess accumulation of extracellular matrix
(ECM) during wound healing [7].
Although a better understanding of the mechanism of
w o u n dh e a l i n gc a nb ep r e s u m e df r o mt h ei n c r e a s e dn u m b e r
of in vitro or in vivo experiments, and a better treatment
algorithm to maintain a regulated and orchestrated inﬂam-
matory response will be developed and result in eﬀective and
normal wound healing [8–10], most in vitro data derived
from ﬁbroblasts cultured from keloid lesions only represent
the terminal stage of this disease and in vivo animal models
might not present a real condition in humans.
2. The Process of Wound Healing and
Skin Inﬂammation
Compared to Drosophila, similar transcription factor regu-
lates formation and maintenance of the epidermal barrier in
mice. These ﬁndings suggest that the mechanisms involving
wound repair have been conserved by forces of evolution for
700 million years [11]. The secret of wound healing might be
hidden in the diﬀerences between fetal and adult skin, and
why fetal wounds heal without a scar in utero [12].
As shown in Figure 1, very little scarring occurs in fetal
skin,whichresultsinnearlyperfectrecoveryoffetalskinafter
trauma. Therefore, understanding the cellular and molecular
processes during wound healing is crucial to clarify the
pathogenesisofhypertrophicscarringanddevelopmoresuc-
cessful treatment modalities (Figure 2). The known process
of normal wound healing involves 3 overlapping phases,
inﬂammation, proliferation, and remodeling. The initial
inﬂammatory phase begins at the time of wounding, when
the activation of the coagulation cascade causes the release
of cytokines that stimulate chemotaxis of neutrophils and
macrophages into the wound to begin early debridement.
This will proceed for 2 to 3 days and then the proliferative
phase, signiﬁed by an abundance of ﬁbroblasts and an
accumulation of ECM, fades in and lasts for 3–6 weeks. The
follow-up ﬁnal remodeling, or the mature phase, may take
6–9 months. The abundant ECM is then degraded and the
immature type III collagen of the early wound is modiﬁed
into mature type I collagen [13].
3. The Pathogenesis of ExcessiveScarring
Although hypertrophic scarring or keloid formation are
regarded as diﬀerent disease entities based on their patho-
histologicaldata(Figures3and4),theystillsharesomecom-
mon characteristics, including increased ﬁbroblast function,
excessive accumulation of ECM, and the common initial
inﬂammatory phase. Keloid ﬁbroblasts (KFs) are supposed
phenotypicallydiﬀerentfromthoseofhypertrophicscarring,
because patients with keloid diathesis do not always form
abnormal scars [13]. Either an ambiguous beginning of the
inﬂammatory signal of the inﬂammatory phase, extendingMediators of Inﬂammation 3
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Figure 2: Normal process of wound healing. The initial inﬂammatory phase begins at the time of wounding, when the activation of the
coagulation cascade causes the release of cytokines that stimulate chemotaxis of neutrophils and macrophages into the wound to begin early
debridement (1). The proliferative phase is signiﬁed by an abundance of ﬁbroblasts and an accumulation of extracellular matrix (ECM) (2).
The abundant ECM is then degraded and the immature type III collagen of the early wound is modiﬁed into mature type I collagen in ﬁnal
remodeling, or mature phase. A good healing process involves several enhancement factors.
to the proliferative process, or a failure of appropriate degra-
dation and apoptosis may contribute to the pathogenesis of
excessive scarring.
Many local factors are believed to increase the chance of
excessive scarring [14, 15]. A hypertrophic scar often results
from a wound which was closed in great tension, with rough
handling and inadequate hemostasis and debridement, and
material with a powerful foreign body reaction, and without
enough nutrition. These factors, including transforming
growth factor-β (TGF-β) and PG will be reviewed in the in
vitro and in vivo models subsequently.
4. The InVitro Studies
Hypertrophic scars and keloids represent a dysregulated
response to cutaneous injuries, which results in an exces-
sive deposition of collagen. A lot of experiments [16–
25], involving keratinocytes, ﬁbroblasts, myoﬁbroblasts, and
neutrophils, were designed to test presumed important
factors like TGF-β1[ 16], matrix metalloproteinases (MMPs)
[17], and nitric oxide (NO) [18], and to determine whether
the hypertrophic process is turned on or how the aberrant
apoptosis in the healing course is turned oﬀ.A l m o s ta l l
of these studies focused on the aberrant proliferative and
remodeling phases. The main reason is not clear, but the
possible cause is that the prominence of the aberrant expres-
sion of the mediators of wound healing is found during the
proliferative and remodeling phases (see below). However,
the aberrant wound healing process might occur during a
much earlier phase. For example, dysregulated interactions
of both epidermal-derived cytokines (interlukin 1: IL-1 α
and tumor necrotic factor α:T N F - α) and dermal-derived
inﬂammatory/angiogenic mediators in the beginning of the
inﬂammatory phase contributed to excessive wound scarring
[26].
The TGF-β family is a key factor in ﬁbrosis, because it is
involved in many ﬁbrotic diseases [20, 27]. Upregulation or
overexpression of TGF-β in keloid keratinocyes [19]a n dK F
[18, 20, 21] results in excessive ﬁbrosis and increases wound
scarring. Several treatment protocols, including ﬂash lamp
pulsed-dye laser (PDL) [28], exogenous PGE1 [29], PGE2
[1], NO antagonist [18], and TGF-β antagonist [30], could
ameliorate keloid ﬁbrosis, which is mediated by inhibiting
TGF-β production in the wound.
Compared with the well-accepted role of TGF-β in
wound healing, the role of PGE2 is often overlooked,
although evidence shows that an elevated PGE2 level is an
indicator of progression of inﬂammation in various kinds of
cells and variant inﬂammatory diseases [31–36]. In addition,
a lower level of PGs in fetal skin tissue might indicate a
less severe inﬂammatory reaction, which results in little scar
formation after wound healing [12, 37].
PGE2 was shown to decrease ﬁbroblast proliferation,
inhibit collagen synthesis, and enhance the expression of4 Mediators of Inﬂammation
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Figure 3: The hypertrophic scarring healing result. A hypertrophic scar possesses several surface characteristics that distinguish it from
normal scar formation. There are several initiating factors participate the process. Due to a slow and prolonged regression phase, excessive
type III collagens excreted from ﬁbroblasts are accumulated in a direction parallel to epidermal surface. The evolution of myoﬁbroblast from
ﬁbroblast may cause wound retraction in the future.
Table 1: The levels of PGE2 and TGF-beta during the normal and aberrant wound healing process.
Normal Healing Process Excessive Scarring
Phases 1∗ 23 1 2 3
TGF-beta ↑ ↑ ↓ ↑ ↑↑↑ ↑↑
PGE2 ↑ ↑ ↑ ↑ ↓↓↓ ↓↓
Net Eﬀect debrided limited mature unknown excessive delayed
∗1 for inﬂammatory phase, 2 for proliferative phase, and 3 for remodeling phase.
MMPs. KF produced less PGE2 than that produced by
control ﬁbroblasts [35]. Moreover, the antiﬁbrotic eﬀect of
PGE2 during keloid formation was prohibited and could
be restored by exogenous PGE2 supplementation [1]. The
increased collagen synthesis in KF might be due to decreased
PGE2 and cAMP production.
Mechanical compression of the wound may induce
excessive scarring and inﬂuence the release of PGE2 and the
expression of collagenases. PGE2 basal levels in hypertrophic
burn scars were signiﬁcantly lower than those present in nor-
motrophic burn scars [18]. The best prevention and control
of hypertrophy, especially in burn scars, is achieved using
elastocompression, and compression induced a signiﬁcant
increase in the release of PGE2, in both the remission and
active stages, suggesting a role for PGE2 in the process of
hypertrophy remission induced by pressure therapy [38].
Another possible problem is the defect in apoptosis
and growth during excessive scarring, which hinders the
disappearance of both ﬁbroblasts and myoﬁbroblasts at the
end of healing [23]. PGs, a promoter of stem or progenitor
cell proliferation and tissue regeneration, and positively
acting on the downstream of the cascades of apoptosis,
may prevent excessive scarring [39]. Table 1 summarizes the
diﬀerent expressions of TGF-β and PGE2 in the normal and
aberrant process of wound healing.
Besides, PGE2, PGE1, and its analog can increase the
activity of collagenase, which is lower in the supernatants
from hypertrophic scar ﬁbroblasts culture [40]. PGE1 may
have a role in the prevention of hypertrophic scarring by
increasing the activity of type I collagenase [29]. However,
there is still some controversy regarding the eﬀect of PGs on
the process of wound healing. Tranilast, an antiallergic drug
inhibiting the release of substances such as histamine and
prostaglandins from mast cells, was reported to suppress the
collagen synthesis of ﬁbroblasts derived from keloid tissues
[22]. It is also believed to suppress collagen synthesis by
ﬁbroblasts through inhibiting TGF-β1a n dP G E 2p r o d u c t i o n
and cell proliferation by ﬁbroblasts through inhibiting IL-1Mediators of Inﬂammation 5
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Figure 4: The keloid healing result. Several surface characteristics of keloid mark its diﬀerence from hypertrophic scar. However, there is
only one diﬀerence in the initiating factors. There is no remolding phase in this aberrant wound healing process, and ﬁbroblasts will not
eventually turn into myoﬁbroblasts. The abnormal scar is composed of disorganized type I and III collagens with thick irregular branched
septa. On the cut surface, tongue-like advancing edges provoke its local advanced inﬁltrating nature.
production by inﬂammatory cells such as macrophages [41].
Lower levels of PGs after tranilast seemed not to result in
excessive scarring in this situation.
5.The InVivoStudies
Diﬀerent animal models like rat [37, 42, 43], mouse [44–
46], rabbit [47], lamb, and pig [48, 49] were used to test
anti-inﬂammatory response of TGF-β and other mediators
of inﬂammation. However, animal study of speciﬁc phase of
the wound healing process is almost not possible.
An elevated endogenous TGF-β l e v e li na n i m a l si m p e d e s
wound healing and provokes excessive scarring. Elevated
TGF-β and delayed wound healing in transgenic mice
with TGF-β1 overexpression were associated with profound
inﬂammation throughout all stages of wound healing and
no beneﬁt in wound healing [45]. Injection of an antibody
of TGF-β in a rat demonstrated that inhibition of TGF-β
reduced scar formation in adult wound healing [37]. Topical
application of a synthetic TGF-β antagonist accelerated re-
epithelialization in pig burn wounds. It also reduced wound
contraction and scarring in standard pig skin burns, pig skin
excision, and rabbit skin excision wounds [47, 49].
An initial inﬂammatory response with elevated PGE2
can be eﬀectively blocked by medicine or even dietary fat
in animal models. A toxin-induced inﬂammatory response
characterized by an early exudative phase is accompanied by
PGE2 production, and a late proliferative phase associated
with COX-2 induction is eﬀectively inhibited by COX-2
inhibitors in rats [43]. Modiﬁcation of dietary fat intake
might inhibit fever via a reduced release of PG, probably
within the brain, but does not aﬀect the local or aﬀerent
signals involved in fever generation [50].
Mechanical stress in the proliferative phase was necessary
toreplicatehypertrophicscarformationinamousemodelof
hypertrophic scarring. It is believed that mechanical loading
early in the proliferative phase of wound healing produces
hypertrophic scars by inhibiting cellular apoptosis [46].
However, an animal that does not form keloid growth like
a human does cannot be an ideal model for research.
6. The VariousModalitiesof Treatment
As reported in the studies mentioned above, many treatment
modalities for excessive scarring have been proposed, but no
complete and satisfying remission has been achieved. The
treatment modalities include surgical excision, radiation,
corticosteroid injections, cryotherapy, laser vaporization,
topical 5-ﬂuorouracil [51], bleomycin injection [52], paper
tape to eliminate scar tension [53], pressure garment therapy
[54], silicone gel sheeting [55], and short-term use of
ozonated oil [56, 57]. Since we still lack an in-depth
understanding of the underlying mechanism responsible for
excessive inﬂammation and scarring, no single modality
has shown an absolute, complete cure rate. At present,
the multimodality approach to scarring control has shown
signiﬁcant beneﬁts [56–58]. The most eﬀective of the scar-
reducing protocols likely entails a polytherapeutic strategy
for management. Further investigation into the role of
inﬂammation in scarring is paramount to the development6 Mediators of Inﬂammation
of improved scar-reducing agents. There is a need for
large controlled trials using a polytherapeutic strategy that
combinesexistingandnovelagentstoprovideastandardized
evidence-based evaluation of eﬃcacy [9].
A rising number of novel therapeutic agents, like TGF-
β antagonists [47, 49], exogenous PGE2 [1], and stem cell
therapy [59], are currently under development, encouraged
by emerging preliminary ﬁndings in both animal models
and human studies. The hypertrophic scar/keloid treatment
algorithms that are currently available are likely to be
signiﬁcantly improved in the future by high-quality clinical
trials.
7. The Study Models
A detailed quantitative model of the wound healing process,
including re-epithelialization, epidermal diﬀerentiation, cell
migration, proliferation, inﬂammatory response, dermal
closure, matrix distribution, and skin remodeling, may
be utilized as a diagnostic platform for standardizing the
assessment of wound healing progression, as well as a
screening tool for potential therapies [60].
With advances in biomolecular techniques, high-
throughput study tools make a genomic or proteomic scale
study of the inﬂammatory cascade become possible [61],
and a biochemical model or so-called inﬂammatomics study
will aid in understanding the overall picture of the healing
process after injury.
On the other hand, a more ideal in vivo model, other
than an animal model, is required for clinical studies. The
g r o u po fp a t i e n t ss u ﬀering from excessive scarring after
Cesarean section seems a good model, because it is the most
frequent and common surgical procedure in reproductive-
age women. In addition, these women have an opportunity
to remove the hypertrophic scar or keloid lesion, since many
become pregnant again and schedule an elective repeated
Cesarean section. Therefore, a useful treatment modality to
prevent the recurrence of hypertrophic scarring after scar
removal is needed and worthy of research. In fact, there
are some reports on the reduced scar formation after an
improvement has been made in surgical techniques [62, 63].
8. Conclusion
Better understanding of the pathogenesis of wound healing
will eventually contribute to progress in the treatment of
excessive scarring. Whether excessive scarring occurs or not
mightbedecidedatthemomentwhentheﬁrstinﬂammation
response is initiated once the wound is established. PGEs
might play a role in the prevention of excessive scarring.
A thorough study and understanding of the inﬂammatory
cascade will help us cope with a lot of diseases, including
hypertrophic scarring and keloid.
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